NCT05443932View on ClinicalTrials.gov

Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 4, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
UrolithiasisHyperoxaluria
Interventions
DRUG

Dapagliflozin

10mg Dapagliflozin daily for 8 weeks

DRUG

Hydrochlorothiazide

50mg Hydrochlorothiazide daily for 8 weeks

Trial Locations (1)

1090

Medical University of Vienna, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT05443932 - Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients | Biotech Hunter | Biotech Hunter